ECSP12012317A - Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs) - Google Patents

Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)

Info

Publication number
ECSP12012317A
ECSP12012317A ECSP12012317A ECSP12012317A EC SP12012317 A ECSP12012317 A EC SP12012317A EC SP12012317 A ECSP12012317 A EC SP12012317A EC SP12012317 A ECSP12012317 A EC SP12012317A
Authority
EC
Ecuador
Prior art keywords
fxs
treatment
predictive markers
useful predictive
fragile
Prior art date
Application number
Other languages
English (en)
Inventor
Mancilla Baltazar Gomez
Yunsheng He
Donald Johns
Joanne Meyer
Charles Paulding
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44121075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012317(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP12012317A publication Critical patent/ECSP12012317A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere al uso de biomarcadores para determinar la posibilidad de respuesta de un individuo con síndrome X frágil (FXS) al tratamiento con un antagonista del receptor de glutamato metabotrópico 5 (mGluR5).
ECSP12012317 2010-04-30 2012-11-29 Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs) ECSP12012317A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33029910P 2010-04-30 2010-04-30
US37919710P 2010-09-01 2010-09-01

Publications (1)

Publication Number Publication Date
ECSP12012317A true ECSP12012317A (es) 2013-01-31

Family

ID=44121075

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012317 ECSP12012317A (es) 2010-04-30 2012-11-29 Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)

Country Status (21)

Country Link
US (1) US20130052644A1 (es)
EP (1) EP2563934A1 (es)
JP (1) JP2013524840A (es)
KR (1) KR20130100906A (es)
CN (1) CN102869791A (es)
AU (1) AU2011245372A1 (es)
BR (1) BR112012027816A2 (es)
CA (1) CA2797854A1 (es)
CL (1) CL2012003027A1 (es)
EC (1) ECSP12012317A (es)
GT (1) GT201200293A (es)
IL (1) IL222534A0 (es)
MA (1) MA34263B1 (es)
MX (1) MX2012012615A (es)
PE (1) PE20130213A1 (es)
RU (1) RU2012151273A (es)
SG (1) SG184458A1 (es)
TN (1) TN2012000485A1 (es)
TW (1) TW201142293A (es)
WO (1) WO2011137206A1 (es)
ZA (1) ZA201207481B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HRP20220796T1 (hr) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe
WO2012084873A1 (en) * 2010-12-20 2012-06-28 Novartis Ag 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
WO2013131981A1 (en) 2012-03-08 2013-09-12 Novartis Ag Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs)
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152600A2 (en) * 2013-03-15 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Measurement of cellular fmrp levels for high throughput drug screening and diagnosis of fragile x syndrome
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
CA2926645C (en) 2013-10-14 2022-10-25 Indiana University Research And Technology Corporation Use of acamprosate to modulate erk 1/2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd
CN103981253A (zh) * 2014-03-27 2014-08-13 江苏佰龄全基因生物医学技术有限公司 一种用于检测脆性x染色体综合征的cgg重复数及agg插入信息的pcr试剂盒
EP4244631A1 (en) * 2020-11-13 2023-09-20 Children's Hospital Medical Center Refined uses of gabaa receptor modulators in treatment of fragile x syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6143504A (en) * 1998-10-27 2000-11-07 Arch Development Corporation Methods and compositions for the diagnosis of fragile X syndrome
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
JP4453297B2 (ja) 2003-05-27 2010-04-21 トヨタ自動車株式会社 車両用遊星歯車式多段変速機
TW200801005A (en) 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
US20090042195A1 (en) * 2005-10-07 2009-02-12 Bradford Coffee Methods and systems for screening for and diagnosing dna methylation associated abnormalities and sex chromosome aneuploidies
US7855053B2 (en) * 2006-07-19 2010-12-21 The Regents Of The University Of California Methods for detecting the presence of expanded CGG repeats in the FMR1 gene 5′ untranslated region
US20110136146A1 (en) 2008-08-04 2011-06-09 Novartis Ag Bioassay for polyq protein
US20100248239A1 (en) * 2009-03-24 2010-09-30 Mayo Foundation For Medical Education And Research Methods and materials for detecting fragile x mutations

Also Published As

Publication number Publication date
US20130052644A1 (en) 2013-02-28
TN2012000485A1 (en) 2014-04-01
JP2013524840A (ja) 2013-06-20
GT201200293A (es) 2014-06-09
PE20130213A1 (es) 2013-03-19
MA34263B1 (fr) 2013-05-02
ZA201207481B (en) 2013-06-26
EP2563934A1 (en) 2013-03-06
BR112012027816A2 (pt) 2017-08-08
AU2011245372A1 (en) 2012-11-29
WO2011137206A1 (en) 2011-11-03
CN102869791A (zh) 2013-01-09
CL2012003027A1 (es) 2014-02-14
KR20130100906A (ko) 2013-09-12
TW201142293A (en) 2011-12-01
SG184458A1 (en) 2012-11-29
CA2797854A1 (en) 2011-11-03
IL222534A0 (en) 2012-12-31
MX2012012615A (es) 2012-12-17
RU2012151273A (ru) 2014-06-10

Similar Documents

Publication Publication Date Title
ECSP12012317A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
DE602007012072D1 (de) Orantagonisten
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
ECSP13013022A (es) Agonistas de fgfr1 y sus métodos de uso
CL2011000976A1 (es) Compuestos derivados de isonicotinamida y carboxamida, antagonistas de los receptores de orexina; composicion farmaceutica que los comprende; y su uso para la prevencion de un trastorno del sueno.
DK2491037T3 (da) Quinazolin-4(3h)-onderivater, der anvendes som pi3-kinase-inhibitorer
CL2012002296A1 (es) Polipeptido porque comprende un dominio decimo de fibronectina de tipo iii y que se une a interleucina 23 (il-23); composicion farmacéutica que comprende dicho polipeptido; procedimiento para regular la patogenicidad de los linfocitos th17 que comprende poner en contacto el polipeptido antes mencionado con il-23.
NO20084779L (no) Behandling av idiopatisk pulmonell fibrose i tidlig stadium
DK2225256T3 (da) Nye glucocorticoidreceptoragonister
ECSP11011557A (es) Mimético de smac
DK2197900T3 (da) Mutante dobbeltringsluttede receptorpeptider, der inhiberer beta1-adrenoreceptorantistoffer
UY34666A (es) Inhibidores de quinasa a base de ariléter
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
UY33856A (es) ?gen y variaciones asociadas con el fenotipo bm1, marcadores moleculares y su uso?.
ES2572368T3 (es) Tratamiento de la artrosis
ES2511056T3 (es) Biomarcadores para esquizofrenia u otros trastornos psicóticos
CL2012002543A1 (es) Composicion endoparasiticida que comprende una combinacion de un compuesto de formula (i) derivado de amidoacetonitrilo y abamectina; y su uso para el control de endoparasitos, en particular helmintos.
IT1400311B1 (it) Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
CL2008001972A1 (es) Uso de un ligando endogeno canabinoide como biomarcador de aptitud para el tratamiento con una droga antagonista de receptor canabinoide.
CL2013003083A1 (es) Compuestos derivados de sulfonamido bencil oxadiazol con actividad antagonista del receptor npy y5; composición farmacéutica que los comprende; útiles en el tratamiento de la obesidad, depresión, hipertensión, insuficiencia cardiaca congestiva, trastornos del sueño, entre otros.
IT1400309B1 (it) Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
UA33402U (ru) Использование антагониста рецепторов интерлейкина-1 в качестве средства с антигипоксическим действием
RU2009149018A (ru) Железнодорожная аппарель из элементов малого автодорожного моста
UA50733U (ru) Применение антагониста рецепторов интерлейкина-1 (АРИЛ-1) в качестве средства антиалкогольного действия
UA51902U (ru) Применение антагониста рецепторов интерлейкина-1 (арил-1) в качестве способа фригопротекторного действия